-
公开(公告)号：US11254750B2
公开(公告)日：2022-02-22
申请号：US17080626
申请日：2020-10-26
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron Yamniuk , Mary Struthers , Stanley R. Krystek, Jr. , Akbar Nayeem , Ginger Rakestraw
IPC: C07K16/28 , A61K39/395 , C07K16/46 , A61P37/00 , A61K47/68 , A61K45/06 , A61K39/00 , C07K14/705
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
Patent Agency Ranking
公开(公告)号：US11795231B2
公开(公告)日：2023-10-24
申请号：US17670223
申请日：2022-02-11
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron Yamniuk , Mary Struthers , Stanley R. Krystek, Jr. , Akbar Nayeem , Ginger Rakestraw
IPC: C12N15/63 , C07K16/28 , A61K39/395 , A61K47/68 , C07K16/46 , A61P37/00 , A61K45/06 , A61K39/00 , C07K14/705
CPC classification number: C07K16/2878 , A61K39/3955 , A61K47/68 , A61K47/6849 , A61P37/00 , C07K16/468 , C12N15/63 , A61K45/06 , A61K47/6803 , A61K2039/505 , C07K14/70578 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/565 , C07K2317/622 , C07K2317/71 , C07K2317/76 , C07K2317/92
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
公开(公告)号：US11926673B2
公开(公告)日：2024-03-12
申请号：US17579468
申请日：2022-01-19
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron Yamniuk , Mary Struthers , Stanley R. Krystek, Jr. , Akbar Nayeem , Ginger Rakestraw
IPC: A61K39/395 , A61K47/68 , A61P37/00 , C07K16/28 , C07K16/46 , C12N15/63 , A61K39/00 , A61K45/06 , C07K14/705
CPC classification number: C07K16/2878 , A61K39/3955 , A61K47/68 , A61K47/6849 , A61P37/00 , C07K16/468 , C12N15/63 , A61K2039/505 , A61K45/06 , A61K47/6803 , C07K14/70578 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/565 , C07K2317/622 , C07K2317/71 , C07K2317/76 , C07K2317/92
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
公开(公告)号：US11773178B2
公开(公告)日：2023-10-03
申请号：US17588518
申请日：2022-01-31
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron Yamniuk , Mary Struthers , Stanley R. Krystek, Jr. , Akbar Nayeem , Ginger Rakestraw
IPC: C12N15/63 , C07K16/28 , A61K39/395 , A61K47/68 , C07K16/46 , A61P37/00 , A61K45/06 , A61K39/00 , C07K14/705
CPC classification number: C07K16/2878 , A61K39/3955 , A61K47/68 , A61K47/6849 , A61P37/00 , C07K16/468 , C12N15/63 , A61K45/06 , A61K47/6803 , A61K2039/505 , C07K14/70578 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/565 , C07K2317/622 , C07K2317/71 , C07K2317/76 , C07K2317/92
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
公开(公告)号：US11623965B2
公开(公告)日：2023-04-11
申请号：US16103654
申请日：2018-08-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Stanley R. Krystek, Jr. , Yong Zhang , Gregory D. Vite , Arvind Rajpal , Chetana Rao-Naik , Paul E. Morin , Mohan Srinivasan , Zheng Lin , Virginie Lafont , Alla Pritsker
Abstract: A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.
-
公开(公告)号：US11261258B2
公开(公告)日：2022-03-01
申请号：US16686596
申请日：2019-11-18
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron Yamniuk , Mary Struthers , Stanley R. Krystek, Jr. , Akbar Nayeem , Ginger Rakestraw
IPC: A61K39/395 , C07K16/28 , A61K47/68 , C07K16/46 , C07K14/705 , A61K45/06 , A61K39/00
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
-
-
-
-
Search Results
6
records
(took 0.015 seconds)
